GILEAD SCIENCES SL

The U.S. completed an initial shipment of Marburg vaccine doses and therapeutic drugs to Rwanda on Oct. 4. The U.S. is collaborating with international partners and Rwanda’s health ministry on clinical trials. Rwanda detected its first Marburg outbreak in late September, with 36 cases and 11 deaths. The Sabin Vaccine Institute delivered 700 doses of its vaccine for trials targeting frontline workers. Gilead Sciences donated 5,000 vials of remdesivir for emergency use.

Gilead Sciences' HIV prevention drug, Lenacapavir, will be available in 120 countries, excluding high-incidence nations like Brazil and Mexico. The drug, administered twice yearly, has shown high efficacy in clinical trials, but critics argue for broader access to combat the global HIV epidemic.

Experimental Marburg vaccines and therapeutics, including Gilead's remdesivir and Mapp's MBP-091, will soon arrive in Rwanda for clinical trials. Rwanda, facing its first Marburg outbreak with 41 cases, aims to start trials within days to protect healthcare workers. The Sabin Vaccine Institute is sending 700 doses of a single-dose vaccine, believed to be the furthest along in development.

The LLC model offers flexibility in deal structures, clear IP ownership, and efficient capital recycling, making it attractive for biotech companies like Nimbus Therapeutics. However, it may not suit all companies, particularly those with complex IP portfolios, and requires adaptable talent management.

Gilead to donate 5,000 vials of remdesivir to Rwanda for emergency use against Marburg Virus Disease outbreak, pending Rwanda FDA authorization. Remdesivir, not approved for MVD treatment globally, has broad-spectrum antiviral activity and was used in COVID-19 treatment.

A new HIV prevention drug, lenacapavir, shows 100% efficacy in clinical trials when injected every six months, with no infections reported among women in Uganda and South Africa. Initial results from a separate trial show 99% protection rates among men who have sex with men, transgender, and non-binary people. Gilead Sciences, the manufacturer, is under pressure to lower the current $42,000 annual treatment price and has signed licensing agreements with generic manufacturers to increase global access.

Gilead Sciences partners with six pharma manufacturers to produce generic lenacapavir for HIV prevention and treatment, aiming to sell in 120 resource-limited countries, addressing HIV advocacy groups' calls for affordability.

A new HIV prevention drug, lenacapavir, shows 100% efficacy in clinical trials when injected every six months, with no infections reported among women participants. Developed by Gilead Sciences, lenacapavir is currently priced at $42,000 per year for treatment but is not yet approved for prevention. Gilead has signed licensing agreements with generic drug manufacturers to produce low-cost versions for 120 countries and plans to seek regulatory approval by 2024.

Gilead Sciences permits six generic companies in Asia and North Africa to produce lenacapavir, a twice-yearly HIV-prevention injection, for 120 countries, including those in sub-Saharan Africa with high HIV rates, at no licensing cost.

Gilead Sciences to make cheaper lenacapavir available in 120 low- and middle-income countries; campaigners criticize exclusion of high HIV burden countries, especially in Latin America; UNAids calls for universal access and transparency on pricing.